Levocetirizine dihydrochloride Good Manufacturer supply High Quality 130018-87-0
- Molecular Formula:C21H25ClN2O3*2ClH
- Molecular Weight:461.816
- Appearance/Colour:white or off-white crystalline powder
- Melting Point:215-220 °C
- Boiling Point:542.1 °C at 760 mmHg
- Flash Point:281.6 °C
- PSA：53.01000
- LogP:4.62800
Levocetirizine dihydrochloride (130018-87-0) Usage
Levocetirizine dihydrochloride, also known as (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride or Xyzal, is a white, crystalline powder that is water-soluble. This R-enantiomer has a 30-fold higher affinity than the S-enantiomer and dissociates more slowly from H1-receptors. Pharmacologically, it exhibits the same receptor and CNS selectivity profile as the racemate, cetirizine, and thus shares the same therapeutic advantages.
How to get the best price on Levocetirizine dihydrochloride?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Levocetirizine dihydrochloride . You can buy high quality, low price Levocetirizine dihydrochloride 130018-87-0 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
